136434-34-9 (S)-Duloxetine HCl AKSci J10476
 
 
Loading Please Wait...
  J10476    AKSci Reference Standard
(S)-Duloxetine HCl, 99% (HPLC), powder
 
(gamma-S)-N-Methyl-(1-naphthalenyloxy)-2-thiophenepropanamine hydrochloride
(+)-(S)-N-Methyl-gamma-(1-naphthyloxy)-2-thiophenepropylamine hydrochloride
(+)-N-Methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine hydrochloride
more..
IDENTITY
CAS Number:136434-34-9
MDL Number:MFCD06407958
MF:C18H20ClNOS
MW:333.88
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:99% (HPLC), powder
Physical Form (at 20°C):Solid
Melting Point:162-172°C
Boiling Point:64-65°C (0.760mmHg)
Flash Point:9.7°C
Optical Rotation:+116.0° - +125.0° (c=1, MeOH)
Density:0.791
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:H2O: soluble5 mg/mL (clear solution, warmed)
Application(s):Serotonin-norepinephrine reuptake inhibitor
Form:HCl salt

REVIEW
 Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.

REFERENCES
[1]Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P: Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001 May;24(5):511-21.
[2] Anttila S, Leinonen E: Duloxetine Eli Lilly. Curr Opin Investig Drugs. 2002 Aug;3(8):1217-21.
[3] Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76.
[4] van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Danger

Hazard Statements
H225; H301+H311+H331; H370

Precautionary Statements
P210; P233; P240; P241; P242; P243; P260; P264; P270; P271; P280; P301+P310; P303+P361+P353; P304+P340; P307+P311; P322; P330; P361; P363; P370+P378; P403+P233; P403+P235; P405; P501

Current as of April 25, 2024

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives > Antidepressants


PubChem